ArmaGen Technologies is both a platform technology company and a products company. The platform technology produces IgG fusion proteins formed by fusion of a recombinant protein therapeutic, which does not cross the BBB to an IgG. The IgG domain of the fusion protein is a genetically engineered monoclonal antibody, which crosses the human BBB via transport on endogenous BBB receptors. The IgG domain acts as a molecular Trojan horse to ferry the fused pharmaceutical agent across the BBB from blood. ArmaGen has used the platform technology to develop a diverse pipeline of BBB penetrating recombinant protein therapeutics, including lysosomal enzymes, neurotrophins, decoy receptors, or therapeutic antibodies.www.armagen.com About Victoria Sergeant & Associates http://vsergeant.com/index.html Contact: James Callaway, CEO858-967-1471 email@example.com SOURCE ArmaGen Technologies, Inc.